Pattern of progression in advanced HCC treated with ramucirumab/placebo: Results from two randomized phase III trials (REACH/REACH-2)

被引：0
|
作者：
Reig, Maria
Galle, Peter R.
Kudo, Masatoshi
Finn, Richard S.
Llovet, Josep M.
Schelman, William R.
Liang, Kun
Wang, Chunxiao
Widau, Ryan C.
Abada, Paolo
Zhu, Andrew X.
机构：
[1] Hosp Clin Barcelona, Barcelona Clin Liver Canc Grp, Liver Unit, IDIBAPS,CIBEREHD, Barcelona, Spain
[2] Univ Med Mainz, Mainz, Germany
[3] Kindai Univ, Fac Med, Osaka, Japan
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] Eli Lilly & Co, Indianapolis, IN 46285 USA
[7] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
544
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer
    Tabernero, Josep
    Ohtsu, Atsushi
    Muro, Kei
    Van Cutsem, Eric
    Oh, Sang Cheul
    Bodoky, Gyorgy
    Shimada, Yasuhiro
    Hironaka, Shuichi
    Ajani, Jaffer A.
    Tomasek, Jiri
    Safran, Howard
    Chandrawansa, Kumari
    Hsu, Yanzhi
    Heathman, Michael
    Khan, Azhar
    Ni, Lan
    Melemed, Allen S.
    Gao, Ling
    Ferry, David
    Fuchs, Charles S.
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10) : 2215 - 2222
  • [32] Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2
    Galle, Peter R.
    Kudo, Masatoshi
    Llovet, Josep M.
    Finn, Richard S.
    Karwal, Mark
    Pezet, Denis
    Kim, Tae-You
    Yang, Tsai-Sheng
    Zagonel, Vittorina
    Tomasek, Jiri
    Phelip, Jean Marc
    Touchefeu, Yann
    Koh, Su-Jin
    Stirnimann, Guido
    Wang, Chunxiao
    Ogburn, Kenyon
    Abada, Paolo
    Widau, Ryan C.
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [33] Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study
    Gandara, David R.
    von Pawel, Joachim
    Mazieres, Julien
    Sullivan, Richard
    Helland, Aslaug
    Han, Ji-Youn
    Ponce Aix, Santiago
    Rittmeyer, Achim
    Barlesi, Fabrice
    Kubo, Toshio
    Park, Keunchil
    Goldschmidt, Jerome
    Gandhi, Mayank
    Yun, Cindy
    Yu, Wei
    Matheny, Christina
    He, Pei
    Sandler, Alan
    Ballinger, Marcus
    Fehrenbacher, Louis
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (12) : 1906 - 1918
  • [34] Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
    Chau, I.
    Park, J. O.
    Ryoo, B. Y.
    Yen, C. J.
    Poon, R.
    Pastorelli, D.
    Blanc, J. F.
    Kudo, M.
    Pfiffer, T. F.
    Hatano, E.
    Chung, H. C.
    Kubackova, K.
    Phelip, J. M.
    Brandi, G.
    Ohkawa, S.
    Li, C. P.
    Okusaka, T.
    Yang, L.
    Abada, P.
    Zhu, A.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S446 - S446
  • [35] Alefacept treatment results in clinically meaningful improvement in patients with chronic plaque psoriasis: Results from two randomized, placebo-controlled phase III trials
    Balkrishnan, R
    Feldman, SR
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2003, 121 (06) : 1569 - 1569
  • [36] Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma (HCC): collective results from the phase III sorafenib HCC assessment randomized protocol (SHARP) and Asia-Pacific (AP) trials
    Llovet, J.
    Cheng, A.
    Qin, S.
    Shan, M.
    Nadel, A.
    Burock, K.
    Forner, A.
    Zou, J.
    Bruix, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 367 - 367
  • [37] Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study
    Chau, Ian
    Peck-Radosavljevic, Markus
    Borg, Christophe
    Malfertheiner, Peter
    Seitz, Jean Francois
    Park, Joon Oh
    Ryoo, Baek-Yeol
    Yen, Chia-Jui
    Kudo, Masatoshi
    Poon, Ronnie
    Pastorelli, Davide
    Blanc, Jean-Frederic
    Chung, Hyun Cheol
    Baron, Ari D.
    Okusaka, Takuji
    Bowman, L.
    Cui, Zhanglin Lin
    Girvan, Allicia C.
    Abada, Paolo B.
    Yang, Ling
    Zhu, Andrew X.
    EUROPEAN JOURNAL OF CANCER, 2017, 81 : 17 - 25
  • [38] Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials
    Papp, K. A.
    Menter, M. A.
    Abe, M.
    Elewski, B.
    Feldman, S. R.
    Gottlieb, A. B.
    Langley, R.
    Luger, T.
    Thaci, D.
    Buonanno, M.
    Gupta, P.
    Proulx, J.
    Lan, S.
    Wolk, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (04) : 949 - 961
  • [39] The primary results of an intergroup phase III randomized controlled trial comparing ramucirumab plus irinotecan with irinotecan in the third or later line treatment beyond progression after ramucirumab for advanced gastric cancer (RINDBeRG trial)
    Kadowaki, S.
    Sakai, D.
    Kawabata, R.
    Hara, H.
    Yasui, H.
    Takahashi, M.
    Hirao, M.
    Imai, H.
    Minashi, K.
    Kawakami, T.
    Satake, H.
    Matsuyama, J.
    Sakamoto, Y.
    Sawada, K.
    Kataoka, M.
    Kawakami, H.
    Shimokawa, T.
    Boku, N.
    Satoh, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1317 - S1318
  • [40] Predicting Treatment Responses in Patients With Osteoarthritis: Results From Two Phase III Tanezumab Randomized Clinical Trials
    Colloca, Luana
    Dworkin, Robert H.
    Farrar, John T.
    Tive, Leslie
    Yang, Jiyue
    Viktrup, Lars
    Dasic, Gorana
    West, Christine R.
    Whalen, Ed
    Brown, Mark T.
    Gilbert, Steven A.
    Verburg, Kenneth M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2023, 113 (04) : 878 - 886
12345